Abstract

BackgroundAK106-001616 (AK106) is a selective cytosolic phospholipase A2 (cPLA2) inhibitor with a novel mechanism of action as an anti-inflammatory/analgesic drug. Unlike non-steroidal anti-inflammatory drugs (NSAIDs), AK106 inhibits the production of...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial
Bruno François ...
The Lancet Infectious Diseases | VOL. 21
Bruno François, et. al.Bruno François ...
21 Apr 2021
FRI0186 Impact of Concomitant Methotrexate Dose on the Efficacy and Safety of Sarilumab for Treatment of Moderate-to-Severe Rheumatoid Arthritis: The Mobility Study
T.W.J Huizinga ... Y Yazici
Annals of the Rheumatic Diseases | VOL. 74
T.W.J Huizinga, et. al.T.W.J Huizinga ... Y Yazici
01 Jun 2015
P136 Efficacy and safety of olokizumab in a phase III trial in patients with moderately to severely active RA inadequately controlled by TNF-α inhibitor therapy
Eugen Feist ... Mikhail Samsonov
Rheumatology (Oxford, England) | VOL. 60
Eugen Feist, et. al.Eugen Feist ... Mikhail Samsonov
25 Apr 2021
PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial
Atanaska Elenkova ... Andrea Giustina
Journal of the Endocrine Society | VOL. 6
Atanaska Elenkova, et. al.Atanaska Elenkova ... Andrea Giustina
01 Nov 2022
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
Matthew A Brown ... Irene Van Der Horst-Bruinsma
Annals of the Rheumatic Diseases | VOL. -
Matthew A Brown, et. al.Matthew A Brown ... Irene Van Der Horst-Bruinsma
08 Jul 2024
Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease
Yusuke Yoshimura ... Naoki Sawa
Annals of the Rheumatic Diseases | VOL. -
Yusuke Yoshimura, et. al.Yusuke Yoshimura ... Naoki Sawa
04 Jul 2024
Acod1-mediated inhibition of aerobic glycolysis suppresses osteoclast differentiation and attenuates bone erosion in arthritis
Katerina Kachler ... Aline Bozec
Annals of the Rheumatic Diseases | VOL. -
Katerina Kachler, et. al.Katerina Kachler ... Aline Bozec
04 Jul 2024
Haematopoietic stem cell-derived immune cells have reduced X chromosome inactivation skewing in systemic lupus erythematosus
Amy L Roberts ... Timothy J Vyse
Annals of the Rheumatic Diseases | VOL. -
Amy L Roberts, et. al.Amy L Roberts ... Timothy J Vyse
27 Jun 2024
View more papers